Residual metabolic effect after cessation of liraglutide therapy in patients with type 2 diabetes

Margarita Samsonova; Ekaterina Shestakova

doi:10.1530/endoabs.90.EP338

Objective: The aim of our study was to evaluate the possibility of maintaining the metabolic effects of liraglutide 3.0 mg treatment after it’s cessation.

Methods: The study included 8 patients with type 2 diabetes (T2D) and obesity who received liraglutide 3.0 mg daily for 9 months. All of them successfully reduced body weight, insulin resistance level (IR), volume of visceral adipose tissue, HbA1c level. After discontinuation of liraglutide in 2019, these patients did not use GLP-1 analog therapy for 3 years. After 3 years patients were assessed for the following: weight, BMI, glucose, insulin, HbA1c, body composition, hyperinsulinemic euglycemic clamp test with M-index evaluation. Results were compared with similar data collected in 2019 before the start of GLP-1 analog therapy (0-month point), 9 months after the start (9-month point), 3 years after cessation (45-month point).

Findings: BMI did not significantly change between 9-month and 45-month points, though the amount of total and visceral fat increased. Cessation of liraglutide 3.0 mg caused HbA1c deterioration, but according to M-index insulin resistance decreased (Table 1). When comparing data at 0-month and 45-month point we still saw the improvement in fasting glycemia and the non-significant reduction of HbA1c (Table 2).

Table 1 Comparison of data collected on 9-month point and 45-month point
Indicators		Me (Q1;Q3)	P
	9 month	45 month
BMI	37.96 (32.9;40.2)	38.75 (38;43)	0.093
M-index	1.09 (0.96;2.6)	2.58 (1.26;3.5)	0.036
Fasting glucose	6.08 (5.1;6.7)	7 (5.7;8.8)	0.093
Fasting insulin	22.7 (14.3;30)	12.2 (7.3;17.1)	0.012
HbA1c	6 (5.5;6.4)	7.1 (5.95;8.6)	0.025
Total fat (%)	37.5 (33;41)	48.6 (40.4;52)	0.012
Visceral adipose tissue (volume)	170 (127.5;212.5)	255.65 (200;287)	0.012

Table 2 Comparison of data collected on 0-month point and 45-month point
Indicators		Me (Q1;Q3)	P
	0 month	45 month
BMI	42.52 (38.5;43.5)	38.75 (38;43)	0.207578
M-index	1.295 (0.9;2.2)	2.58 (1.26;3.5)	0.035692
Fasting glucose	9.78 (6.4;11.47)	7 (5.7;8.8)	0.01729
Fasting insulin	18.98 (13.4;30)	12.2 (7.3;17.1)	0.011719
HbA1c	7.95 (7.1;8.6)	7.1 (5.95;8.6)	0.233356
Total fat (%)	39.6 (38.5;42.8)	48.6 (40.4;52)	0.05
Visceral adipose tissue (volume)	215 (142.5;255)	255.65 (200;287)	0.161429

Interpretation: Liraglutide 3.0 mg therapy may possibly have significant long-lasting metabolic effects even after it`s cessation. Funding: RSF grant 22-15-00365.

Endocrine Abstracts

EP338